Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Healthcare
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Knight Therapeutics Inc > BNN Market Call
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Sep 09, 2021 9:48am
107 Views
Post# 33830547

RE:RE:RE:RE:RE:BNN Market Call

RE:RE:RE:RE:RE:BNN Market Call
Chianchin wrote: The base is GUD MNGT frantic buyback so that the share price does not deep below $5 and to $3.90. Only a matter of time to $3.90 and more so faster if GUD MNGT does one more disastrous acquisition


Chi-Chi ... there are no frantic buybacks.  That's poppy-kok.
Not sure how you got to $3.90 but if you can make it happen, I'll free up the cash for it.

Disastorous acquisition ????  Have you seen revenue growth over the past few years or are you not paying attention to the metrics that matter ? man-o-man

And "yes" ... we have had retail shareholder churn - since the company has been in existance.  That is expected as many don't know what they are buying here.  It's just part of the game. 

You can't control it - so find a way to enjoy it !!!  Cheers to the future !!!
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities